Literature DB >> 3929309

Attenuation by electroshock treatment of the haloperidol-induced rise in the binding of 3H-imipramine to rat brain membranes.

A I Barkai, S Kowalik, A Reches, T B Cooper, S Fahn.   

Abstract

Studies were conducted in rats to investigate whether chronic haloperidol treatment, electroshock treatment (EST), or a combination of both affects the high-affinity binding of 3H-imipramine to cerebral membranes. Chronic haloperidol (2 mg/kg SC daily for 28 days) resulted in a significant decrease in the density of binding sites in animals killed 1 h after the last treatment, but binding was markedly enhanced after a "washout" period of 5 days. In animals subjected to EST (20-30 mA, 1.5 s, 60 Hz; three times a week for 4 weeks) and killed 1 h after the last treatment, there were no apparent changes, but when animals were allowed a recovery period of 5 days there appeared to be a slight increase in binding. The marked increase in binding seen after haloperidol withdrawal was no longer apparent in animals treated with both haloperidol and EST, indicating that EST acts to attenuate the increase in binding seen after withdrawal of chronic haloperidol. It is suggested that chronic haloperidol may influence presynaptic recognition sites that regulate serotonin uptake and that EST may interact with haloperidol to "stabilize" these presynaptic sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929309     DOI: 10.1007/bf00427898

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  The attenuation by chronic electroconvulsive treatment of hypothermia induced by histamine H2-receptor stimulants in rats.

Authors:  A Pilc; A Rokosz-Pelc
Journal:  Eur J Pharmacol       Date:  1983-03-25       Impact factor: 4.432

2.  Electroconvulsive shock and reserpine: effects on beta-adrenergic receptors in rat brain.

Authors:  K J Kellar; C S Cascio; D A Bergstrom; J A Butler; P Iadarola
Journal:  J Neurochem       Date:  1981-10       Impact factor: 5.372

3.  Application of an improved cerebroventricular perfusion technique in the rabbit: effects of pentobarbital or haloperidol on monoamine metabolites and proteins in the perfusate.

Authors:  A Barkai; M Budek; D L Brown; R R Fieve
Journal:  Neuropharmacology       Date:  1978-06       Impact factor: 5.250

4.  High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders.

Authors:  S Z Langer; E Zarifian; M Briley; R Raisman; D Sechter
Journal:  Life Sci       Date:  1981-07-20       Impact factor: 5.037

5.  Demonstration of specific high affinity binding sites for [3H] imipramine in human brain.

Authors:  M Rehavi; S M Paul; P Skolnick; F K Goodwin
Journal:  Life Sci       Date:  1980-06-30       Impact factor: 5.037

6.  Electroconvulsive shock prevents dopamine receptor supersensitivity.

Authors:  B Lerer; K Jabotinsky-Rubin; J Bannet; R P Ebstein; R H Belmaker
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

7.  Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.

Authors:  A Reches; H R Wagner; A I Barkai; V Jackson; E Yablonskaya-Alter; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Distribution of imipramine binding sites in the rat brain studied by quantitative autoradiography.

Authors:  A Biegon; T C Rainbow
Journal:  Neurosci Lett       Date:  1983-06-30       Impact factor: 3.046

9.  Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.

Authors:  A Pert; J E Rosenblatt; C Sivit; C B Pert; W E Bunney
Journal:  Science       Date:  1978-07-14       Impact factor: 47.728

Review 10.  Binding of [3H]imipramine and [3H]desipramine as biochemical tools for studies in depression.

Authors:  S Z Langer; R Raisman
Journal:  Neuropharmacology       Date:  1983-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.